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Resistant Hypertension, Time-Updated Blood Pressure Values and
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Giuseppina Russo, MD, PhD; Salvatore De Cosmo, MD; Roberto Pontremoli, MD, PhD; AMD-Annals Study Group*
Background-—Apparent treatment resistant hypertension (aTRH) is highly prevalent in patients with type 2 diabetes mellitus (T2D)
and entails worse cardiovascular prognosis. The impact of aTRH and long-term achievement of recommended blood pressure (BP)
values on renal outcome remains largely unknown. We assessed the role of aTRH and BP on the development of chronic kidney
disease in patients with T2D and hypertension in real-life clinical practice.
Methods and Results-—Clinical records from a total of 29 923 patients with T2D and hypertension, with normal baseline
estimated glomerular filtration rate and regular visits during a 4-year follow-up, were retrieved and analyzed. The association
between time-updated BP control (ie, 75% of visits with BP <140/90 mm Hg) and the occurrence of estimated glomerular filtration
rate <60 and/or a reduction ≥30% from baseline was assessed. At baseline, 17% of patients had aTRH. Over the 4-year follow-up,
19% developed low estimated glomerular filtration rate and 12% an estimated glomerular filtration rate reduction ≥30% from
baseline. Patients with aTRH showed an increased risk of developing both renal outcomes (adjusted odds ratio, 1.31 and 1.43;
P<0.001 respectively), as compared with those with non-aTRH. No association was found between BP control and renal outcomes
in non-aTRH, whereas in aTRH, BP control was associated with a 30% (P=0.036) greater risk of developing the renal end points.
Conclusions-—ATRH entails a worse renal prognosis in T2D with hypertension. BP control is not associated with a more-favorable
renal outcome in aTRH. The relationship between time-updated BP and renal function seems to be J-shaped, with optimal systolic
BP values between 120 and 140 mm Hg. ( J Am Heart Assoc. 2017;6:e006745. DOI: 10.1161/JAHA.117.006745.)
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R esistant hypertension (RH), that is, blood pressure (BP)above target levels despite optimal combination of at
least 3 different drugs, including a diuretic,1–3 is highly
prevalent in patients at high cardiovascular risk, such as those
with diabetes mellitus and chronic kidney disease (CKD).4–6
The real prevalence of RH has been reported to vary
considerably, from 10% to 40%,3,7 because of several
confounding factors, and the term apparent treatment
resistant hypertension (aTRH) should be preferred when
adherence to medications or out-of-office BP are unknown.8
ATRH has been associated with worse cardiovascular
morbidity and mortality9,10 and faster progression of renal
disease in CKD patients,6,11 underscoring the need for early
identification and systematic evaluation and management of
at-risk patients. In a recent, large, 5-year retrospective study
among over 470 000 individuals from the Kaiser Permanente
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Southern California registry, those with RH had a greater risk
for end-stage renal disease (ESRD), ischemic heart event,
congestive heart failure, cerebrovascular accident, and all-
cause mortality. The risk of ESRD and cerebrovascular
accident were 25% and 23% greater, respectively, in RH
compared with non-RH, supporting the linkage between
severity of BP and both outcomes.12
Furthermore, and somewhat unexpectedly, in patients with
aTRH, the achievement of recommended BP control does not
seem to entail any cardiovascular benefit9,13,14 and, possibly,
is associated with a greater renal risk as compared with
patients with uncontrolled aTRH.3 In a recent retrospective
study on a large cohort of treated hypertensive patients in the
United States, low treated BP (systolic BP [SBP] <120 and/or
diastolic BP [DBP] <70 mm Hg) was associated with more
cardiovascular diseases than less-stringent BP control irre-
spective of aTRH.15
These data raise the possibility that a J-curve effect for
cardiovascular and renal disease is present, and perhaps even
more evident, in the subgroup of patients with aTRH who are
likely to be more adherent to treatment, but also show a
worse risk profile.
Specific data on long-term renal outcome in aTRH are
scanty, especially in real-life clinical conditions and with
regard to de novo development of organ damage in high-risk
subgroups. To get more insights on the relationship between
the presence of aTRH, achievement and maintenance of
recommended BP values, and renal outcome, we looked at the
incidence of low estimated glomerular filtration rate (eGFR)
over a 4-year follow-up in a large, real-life cohort of patients
with hypertension and type 2 diabetes mellitus (T2D) in Italy.
Methods
Study Participants
As already reported,6–18 in Italy, diabetes mellitus care is
mostly provided by a public network of approximately 700
diabetes mellitus clinics in which a team of specialists
provides diagnostic confirmation, prevention, and treatment
for diabetes mellitus and its complications through close
patients follow-up and regular checkups.16–18 In the present
study, we analyze a large cohort of patients with T2D followed
up at 134 diabetes mellitus centers in Italy among those
participating in the Italian Association of Clinical Diabetolo-
gists (Associazione Medici Diabetologi) initiative. The analysis
was performed using the data set of electronic medical
From 134 clinics, 64,893 patients aged ≥18 years with type 2 diabetes mellitus evaluated annually   
over 4 years for arterial blood pressure and eGFR with a baseline  classification of albuminuria. 
29,923 from 132 clinics constitute the study population 
Patients excluded according to baseline data:
-14,602 with eGFR<60 mL/min/1.73 m2
-4,642 for missing data about treatment
-1,738 with eGFR<60 mL/min/1.73 m2 in the previous measure if eGFR < 90 mL/min/1.73 m2
-6,848 lacking a second eGFR measurement before the baseline if eGFR < 90 mL/min/1.73 m2
-7,140 with systolic/diastolic blood pressure <140/90 mm Hg not treated for arterial hypertension




• In a large, real-life cohort study in patients with type 2
diabetes mellitus and hypertension in Italy, the presence of
apparent treatment resistant hypertension entails a signif-
icantly greater risk of developing chronic kidney disease
and/or a clinically relevant reduction in estimated glomeru-
lar filtration rate over a 4-year follow-up.
• The achievement and maintenance of recommended blood
pressure values (ie, 75% of visits with blood pressure <140/
90 mm Hg) are associated with a worse renal outcome in
apparent treatment resistant hypertension patients.
• The relationship between achieved blood pressure and renal
function seems to be J-shaped, at least at very low levels,
with optimal systolic blood pressure values between 120
and 140 mm Hg.
What Are the Clinical Implications?
• There is a need for early identification and management of
patients to prevent the development of apparent treatment
resistant hypertension and associated increase in renal
morbidity.
• Reduction of antihypertensive treatment should be consid-
ered in a small, but relevant, proportion of patients in order
to improve renal outcome.
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Table 1. Baseline Characteristics of Study Patients Stratified by ATRH
All No aTRH aTRH
P Valuen=29 923 n=24 934 n=4989
Male sex 16 969 (56.7%) 14 432 (57.9%) 2537 (50.9%) <0.001
Age, y 659 649 678 <0.001
Known duration of diabetes mellitus, y 118 108 118 <0.001
BMI, kg/m2 305 295 315 <0.001
Serum creatinine, lmol/L 7415 7315 7415 0.005
eGFR, mL/min per 1.73 m2 8613 8613 8313 <0.001
Albuminuria 5874 (19.6%) 4772 (19.1%) 1102 (22.1%) <0.001
Microalbuminuria 5121 (17.1%) 4172 (16.7%) 949 (19.0%) <0.001
Macroalbuminuria 753 (2.5%) 600 (2.4%) 153 (3.1%) 0.001
Serum uric acid, lmol/L 315101 311102 33794 <0.001
SUA in the top sex-specific quintile 2878 (19.3%) 2112 (17.1%) 766 (30.0%) <0.001
HbA1c, % 7.31.3 7.21.3 7.31.3 0.049
HbA1c, mmol/mol 55.714.0 55.714.0 56.114.1 0.049
HbA1c ≥7% (≥53 mmol/mol) 15 987 (53.8%) 13 244 (53.5%) 2743 (55.5%) 0.026
Total cholesterol, mmol/L 4.830.96 4.850.97 4.710.93 <0.001
Triglycerides, mmol/L 1.550.98 1.541.00 1.580.89 0.002
Triglycerides ≥150 mg/dL (≥1.69 mmol/L) 8780 (31.2%) 7181 (30.6%) 1599 (34.2%) <0.001
HDL, mmol/L 1.320.38 1.330.38 1.290.37 <0.001
HDL <40M <50F mg/dL (<1.03M <1.29F mmol/L) 8657 (31.2%) 7009 (30.3%) 1648 (36.0%) <0.001
LDL, mmol/L 2.840.85 2.860.85 2.730.82 <0.001
LDL ≥100 mg/dL (≥2.59 mmol/L) 16 483 (59.7%) 14 009 (60.8%) 2474 (54.4%) <0.001
Systolic BP, mm Hg 14317 14217 14818 <0.001
Diastolic BP, mm Hg 819 819 8210 <0.001
BP ≥140/85 mm Hg 21 711 (72.6%) 17 491 (70.1%) 4220 (84.6%) <0.001
Nonproliferative retinopathy 3955 (13.2%) 3301 (13.2%) 654 (13.1%) 0.906
Proliferative retinopathy 1169 (3.9%) 934 (3.7%) 235 (4.7%) 0.002
Lipid-lowering treatment 14 579 (48.7%) 11 716 (47.0%) 2863 (57.4%) <0.001
Treatment with statins 13 456 (45.0%) 10 773 (43.2%) 2683 (53.8%) <0.001
Treatment with fibrates 656 (2.2%) 559 (2.2%) 97 (1.9%) 0.123
No. of antihypertensive drugs 1.61.3 1.21.0 3.60.8 . . .
Antihypertensive treatment 23 106 (77.2%) 18 117 (72.7%) 4989 (100.0%) . . .
Treatment with ACE-Is/ARBs 19 512 (65.2%) 14 767 (59.2%) 4745 (95.1%) . . .
Aspirin 9296 (31.1%) 7354 (29.5%) 1942 (38.9%) <0.001
Antidiabetic therapy
Diet 2177 (7.3%) 1853 (7.4%) 324 (6.5%) 0.018
Oral antidiabetic drugs 20 137 (67.3%) 16 864 (67.6%) 3273 (65.6%) 0.008
Oral antidiabetic drugs and insulin 4559 (15.2%) 3672 (14.7%) 887 (17.8%) <0.001
Insulin 3050 (10.2%) 2545 (10.2%) 505 (10.1%) 0.738
MeanSD or absolute frequency (percentage). Patients’ baseline missing data: known duration of diabetes mellitus in 937 (3.1%), BMI in 1600 (5.3%), serum uric acid in 15 003 (50.1%),
HbA1c in 231 (0.8%), total cholesterol in 2078 (6.9%), triglycerides in 1805 (6%), HDL in 2178 (7.3%), LDL in 2319 (7.7%), and smoking status in 13 650 (45.6%). ACE-Is indicates
angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor antagonists; ATRH, apparent treatment resistant hypertension; BMI, body mass index; BP, blood pressure; eGFR,
estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; SUA, serum uric acid.
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records collected between January 1, 2004 and June 30,
2011. For the purpose of the analysis, we considered only
patients at least 18 years old and with a follow-up evaluation
within 6 months complete for data about BP values, eGFR,
albuminuria (Alb), and information on treatment.
Of 64 893 patients identified, after exclusion of 34 970
patients without a confirmed eGFR value above 60 mL/min,
or medication information, or a diagnosis of hypertension
(SBP <140 mm Hg and DBP <90 mm Hg and not taking
antihypertensive medications at baseline), a total of 29 923
patients from 132 clinics constitute the study population
(Figure 1). The centers involved in the study were homoge-
neously distributed throughout the country.
Study Design
The analysis of the database is an attempt by the Italian
Associazione Medici Diabetologi initiative to identify a set of
indicators that can be used in the context of continuous
quality improvement. Participating centers adopted the same
software systems for everyday management of outpatients,
whereas a specially developed software package allowed us
to extract the information we intended to analyze from all the
clinical databases (Associazione Medici Diabetologi Data
File). Moreover, data from all participating centers were
collected and centrally analyzed anonymously. All patients
gave their informed consent, and internal approval was
obtained by the Associazione Medici Diabetologi Annals
scientific committee.16–18 The current initiative includes
measuring and monitoring glycated hemoglobin (HbA1c),
BP, low-density lipoprotein cholesterol, total and high-density
lipoprotein cholesterol, and triglycerides. The use of specific
classes of drugs was also evaluated. Because normal ranges
for HbA1c varied among centers, the percentage change with
respect to the upper normal value (measured value/upper
normal limit) was estimated and multiplied by 6.0 to allow
comparisons among the centers. Kidney function was
assessed by serum creatinine and urinary albumin excretion
measurements. GFR was estimated for each patient using a
standardized serum creatinine assay and the Chronic Kidney
Disease Epidemiology Collaboration formula.19 Increased
urinary albumin excretion was diagnosed and defined as
Alb if urinary albumin concentration was more than 30 mg/L,
urinary albumin excretion rate was more than 20 mg/min, or
urinary albumin-to-creatinine ratio was more than 2.5 mg/
mmol in men and more than 3.5 mg/mmol in women. At
each participating center, all patients underwent physical
examination and BP measurements according to a




Figure 2. Cumulative incidence of renal outcomes in patients with and without aTRH and T2D. ATRH
indicates apparent treatment resistant hypertension; CI, confidence interval; eGFR, estimated glomerular
filtration rate; T2D, type 2 diabetes mellitus. *P<0.001 vs No-aTRH. Adjusted odds ratios for eGFR
<60 mL/min per 1.73 m2, 1.31 (CI 1.19–1.44; P<0.001), for eGFR reduction >30% from baseline, 1.43 (CI
1.28–1.58; P<0.001), for eGFR <60 or reduction >30% from baseline, 1.30 (CI 1.19–1.42; P<0.001).
DOI: 10.1161/JAHA.117.006745 Journal of the American Heart Association 4
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standardized protocol. BP was measured with the patient in
the sitting position after a 5-minute rest, with a mercury
sphygmomanometer. SBP and DBP were read to the nearest
2 mm Hg. Disappearance of Korotkoff sounds (phase V) was
the criterion for DBP. Three measurements were taken at 2-
minute intervals, and the average value was used to define
clinical SBP and DBP.
The main analysis was aimed at evaluating the association
between aTRH, BP control (BPC), and renal outcome during
the study. For each outcome, visits after the event occurrence
were excluded from the BPC evaluation. The outcomes were:
(1) eGFR less than 60 mL/min per 1.73 m2; (2) a reduction
≥30% from baseline; and (3) a combination of either 1 of the
above end points.
Definition of ATRH and BPC
We defined ATRH as SBP or DBP≥the BP goal while taking ≥3
antihypertensive medications, including a diuretic, or taking
≥4 antihypertensive medications, including a diuretic, regard-
less of BP values at baseline visit. The BP goal of <140/
90 mm Hg used for this analysis is consistent with the
recommended BP goal for patients with diabetes mellitus in
recent guidelines.20,21
Time-updated BPC was defined as >75% of visits with SBP
and DBP <140/90 mm Hg, whereas in secondary analyses
time-updated mean SBP was examined as the average of all
available SBP values before the occurrence of the end point, if
any.
Statistical Analysis
Data are given as mean values SD; categorical variables
are described as frequencies and percentages. Data were
analyzed by mixed models with diabetes mellitus clinics
fitted as random effect considering patients as clusters of
observations to take into account possible differences
across centers. Continuous variables were analyzed with a
Figure 3. Blood pressure changes during follow-up. ATRH indicates apparent treatment resistant hypertension; BP, blood pressure; blood
pressure control (BPC) refers to the proportion of visits with systolic and diastolic blood pressure <140/90 mm Hg.
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Table 3. Baseline Characteristics of Study Patients and Renal Outcomes During the 4-Year Follow-up Stratified by ATRH and BPC
No ATRH No ATRH ATRH ATRH
P Value
BPC No BPC BPC No BPC
n=4198 n=20 736 n=514 n=4475
Male sex 2461 (58.6%) 11 971 (57.7%) 280 (54.5%) 2257 (50.4%) <0.001
Age, y 639 659 659 678 <0.001
Known duration of diabetes mellitus, y 108 118 109 118 <0.001
BMI, kg/m2 295 295 316 325 <0.001
Serum creatinine, lmol/L 7515 7315 7515 7415 <0.001
eGFR, mL/min per 1.73 m2 8614 8613 8313 8313 <0.001
Albuminuria 694 (16.5%) 4078 (19.7%) 91 (17.7%) 1011 (22.6%) <0.001
Microalbuminuria 616 (14.7%) 3556 (17.1%) 81 (15.8%) 868 (19.4%) <0.001
Macroalbuminuria 78 (1.9%) 522 (2.5%) 10 (1.9%) 143 (3.2%) <0.001
Serum uric acid, lmol/L 31478 310107 33988 33695 <0.001
Serum uric acid in the top sex-specific quintile 491 (20.2%) 1847 (18.6%) 114 (36.4%) 720 (32.1%) <0.001
HbA1c, % 7.11.2 7.31.3 7.21.3 7.31.3 <0.001
HbA1c, mmol/mol 5413 5614 5514 5614 <0.001
HbA1c ≥7% (≥53 mmol/mol) 2019 (48.5%) 11 225 (54.5%) 256 (50.6%) 2487 (56.1%) <0.001
Total cholesterol, mmol/L 4.680.95 4.890.97 4.480.83 4.740.94 <0.001
Triglycerides, mmol/L 1.510.94 1.551.01 1.610.89 1.580.89 0.010
Triglycerides ≥150 mg/dL (≥1.69 mmol/L) 1172 (29.5%) 6009 (30.9%) 173 (36.2%) 1426 (33.9%) <0.001
HDL, mmol/L 1.280.39 1.340.37 1.230.37 1.300.37 <0.001
HDL <40M <50F mg/dL (<1.03M <1.29F mmol/L) 1373 (34.8%) 5636 (29.3%) 199 (42.2%) 1449 (35.3%) <0.001
LDL, mmol/L 2.750.84 2.880.85 2.560.76 2.750.83 <0.001
LDL ≥100 mg/dL (≥2.59 mmol/L) 2155 (55.1%) 11 854 (61.9%) 219 (47.2%) 2255 (55.2%) <0.001
Systolic BP, mm Hg 12612 14516 12914 15017 <0.001
Diastolic BP, mm Hg 768 829 779 839 <0.001
BP ≥140/85 mm Hg 893 (21.3%) 16 598 (80.0%) 165 (32.1%) 4055 (90.6%) <0.001
Nonproliferative retinopathy 500 (11.9%) 2801 (13.5%) 59 (11.5%) 595 (13.3%) 0.008
Proliferative retinopathy 139 (3.3%) 795 (3.8%) 24 (4.7%) 211 (4.7%) 0.001
Smokers 453 (18.6%) 1853 (16.7%) 44 (14.9%) 285 (11.7%) <0.001
Lipid-lowering treatment 2427 (57.8%) 9289 (44.8%) 332 (64.6%) 2531 (56.6%) <0.001
Treatment with statins 2246 (53.5%) 8527 (41.1%) 304 (59.1%) 2379 (53.2%) <0.001
Treatment with fibrates 104 (2.5%) 455 (2.2%) 7 (1.4%) 90 (2.0%) 0.205
Antihypertensive treatment 3869 (92.2%) 14 248 (68.7%) 514 (100.0%) 4475 (100.0%) <0.001
Treatment with ACE-Is/ARBs 3069 (73.1%) 11 698 (56.4%) 494 (96.1%) 4251 (95.0%) <0.001
Aspirin 1539 (36.7%) 5815 (28.0%) 197 (38.3%) 1745 (39.0%) <0.001
Antidiabetic therapy
Diet 361 (8.6%) 1492 (7.2%) 36 (7.0%) 288 (6.4%) 0.024
Oral antidiabetic drugs 2807 (66.9%) 14 057 (67.8%) 328 (63.8%) 2945 (65.8%) 0.007
Oral antidiabetic drugs and insulin 555 (13.2%) 3117 (15.0%) 80 (15.6%) 807 (18.0%) <0.001
Insulin 475 (11.3%) 2070 (10.0%) 70 (13.6%) 435 (9.7%) 0.007
The P values refer to the overall significance of logistic mixed regression model for categorical data or linear for continuous variables with blood pressure group as dependent variable.
MeanSD or absolute frequency (percentage). ACE-Is indicates angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor antagonists; aTRH, apparent resistant
hypertension; BMI, body mass index; BP, blood pressure; BPC, blood pressure control; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL-c, high-density
lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol.
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linear mixed regression model and categorical variables by
using a mixed logistic regression model. Odds ratios (ORs)
for each renal outcome were reported with their 95%
confidence interval (95% CI). A multivariate model was
fitted with a complete-case analysis performed, including
patients for which all data were observed. Assuming
linearity of GFR reduction over time, its slope was taken
as a measure of disease progression rate. For each patient,
we calculated the regression coefficient (slope) of linear
regression between eGFR value and the exact time in years
from the first evaluation, including all measurements from
baseline to the 4-year visit. The analyses were carried out
using STATA software (version 14; StataCorp LP, College
Station, TX). P values of <0.05 were considered statistically
significant.
Results
Among the 64 893 patients evaluated annually over 4 years
for arterial BP and eGFR and with a baseline classification for
Alb, a confirmed past eGFR value above 60 mL/min,
complete information about medications, and a diagnosis of
hypertension, 29 923 patients have been selected for the
present analyses (Figure 1).
Table 4. Multivariate Analysis for the Occurrence of 4-Year Renal Outcome
eGFR <60 mL/min per 1.73 m2 eGFR Reduction ≥30% eGFR <60 or Reduction ≥30%
Odds Ratio (95% CI) P Value Odds Ratio (95% CI) P Value Odds Ratio (95% CI) P Value
Male sex 0.80 (0.74–0.87) <0.001 0.74 (0.68–0.80) <0.001 0.76 (0.71–0.82) <0.001
Age (by 10 y) 1.48 (1.41–1.56) <0.001 1.54 (1.45–1.64) <0.001 1.35 (1.29–1.42) <0.001
Duration of diabetes mellitus (by 10 y) 1.00 (0.95–1.05) 0.936 0.97 (0.92–1.02) 0.235 1.00 (0.95–1.04) 0.953
BMI (by 5 kg/m2) 1.09 (1.05–1.14) <0.001 1.08 (1.04–1.13) <0.001 1.07 (1.04–1.11) <0.001
eGFR (by 10 mL/min per 1.73 m2) 0.40 (0.38–0.41) <0.001 1.07 (1.03–1.11) <0.001 0.53 (0.51–0.54) <0.001
Microalbuminuria 1.69 (1.53–1.86) <0.001 1.77 (1.59–1.96) <0.001 1.70 (1.55–1.86) <0.001
Macroalbuminuria 4.49 (3.65–5.52) <0.001 4.23 (3.45–5.19) <0.001 4.05 (3.34–4.92) <0.001
HbA1c ≥7% (≥53 mmol/mol) 1.06 (0.97–1.15) 0.172 1.04 (0.95–1.14) 0.358 1.05 (0.97–1.13) 0.234
Triglycerides ≥150 mg/dL (≥1.69 mmol/L) 1.17 (1.07–1.27) <0.001 1.18 (1.08–1.30) <0.001 1.18 (1.09–1.27) <0.001
HDL <40M <50F mg/dL (<1.03M <1.29F mmol/L) 1.09 (1.00–1.19) 0.039 1.12 (1.02–1.23) 0.017 1.09 (1.01–1.18) 0.024
LDL ≥100 mg/dL (≥2.59 mmol/L) 0.84 (0.78–0.91) <0.001 0.80 (0.73–0.87) <0.001 0.84 (0.79–0.9) <0.001
Nonproliferative retinopathy 1.11 (1.00–1.24) 0.054 1.12 (0.99–1.26) 0.061 1.11 (1.00–1.22) 0.051
Proliferative retinopathy 1.27 (1.06–1.53) 0.009 1.20 (0.99–1.46) 0.062 1.28 (1.08–1.51) 0.004
Lipid-lowering treatment 0.93 (0.86–1.01) 0.090 0.92 (0.84–1.01) 0.071 0.93 (0.86–1.00) 0.041
Antihypertensive treatment 1.42 (1.23–1.64) <0.001 1.35 (1.15–1.58) <0.001 1.37 (1.20–1.56) <0.001
Treatment with ACE-Is/ARBs 0.95 (0.84–1.06) 0.347 0.92 (0.81–1.05) 0.205 0.96 (0.86–1.06) 0.403
Aspirin 1.08 (0.99–1.18) 0.086 1.03 (0.93–1.13) 0.616 1.08 (1.00–1.17) 0.059
Antidiabetic therapy
Diet 0.72 (0.61–0.86) <0.001 0.69 (0.56–0.85) <0.001 0.73 (0.62–0.85) <0.001
Oral antidiabetic drugs 1.00 1.00 1.00
Oral antidiabetic drugs and insulin 1.24 (1.11–1.38) <0.001 1.24 (1.11–1.40) <0.001 1.23 (1.12–1.37) <0.001
Insulin 1.24 (1.09–1.40) 0.001 1.20 (1.04–1.38) 0.010 1.23 (1.09–1.38) 0.001
Group ATRH and BPC
No ATRH and BPC 1.00 1.00 1.00
No ATRH and No BPC 1.05 (0.94–1.18) 0.393 1.00 (0.87–1.13) 0.940 1.04 (0.93–1.16) 0.486
ATRH and BPC 1.78 (1.37–2.32) <0.001 1.87 (1.43–2.45) <0.001 1.68 (1.32–2.15) <0.001
ATRH and No BPC 1.32 (1.15–1.52) <0.001 1.37 (1.18–1.59) <0.001 1.30 (1.14–1.48) <0.001
Blood pressure control (BPC) refers to the proportion of visits with systolic and diastolic blood pressure <140/90 mm Hg. For each renal outcome, visits after the event occurrence were
excluded. Odds ratio for single renal outcome with 95% confidence interval (CI). Complete-case analysis including 24 640 patients for which all data were observed. ACE-Is indicates
angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor antagonists; ATRH, apparent treatment resistant hypertension; BMI, body mass index; BP, blood pressure; eGFR,
estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol.
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Table 5. Baseline Characteristics of Study Patients Stratified by Sex
Women Men
P Valuen=12 954 n=16 969




BMI, kg/m2 306 294 <0.001
Serum creatinine, lmol/L 6411 8113 <0.001
eGFR, mL/min per 1.73 m2 8513 8613 <0.001
Albuminuria 1970 (15.2%) 3904 (23.0%) <0.001
Microalbuminuria 1744 (13.5%) 3377 (19.9%) <0.001
Macroalbuminuria 226 (1.7%) 527 (3.1%) <0.001
Serum uric acid, lmol/L 297111 32990 <0.001
SUA in the top
sex-specific quintile
1189 (18.4%) 1689 (20.0%) 0.015
HbA1c, % 7.41.3 7.21.3 <0.001
HbA1c, mmol/mol 5714 5514 <0.001
HbA1c ≥7% (≥53 mmol/mol) 7362 (57.3%) 8625 (51.2%) <0.001
Total cholesterol, mmol/L 5.010.95 4.700.95 <0.001
Triglycerides, mmol/L 1.520.95 1.571.00 <0.001
Triglycerides ≥150 mg/dL
(≥1.69 mmol/L)
3720 (30.5%) 5060 (31.8%) 0.031
HDL, mmol/L 1.420.39 1.250.35 <0.001
HDL <40M <50F mg/dL
(<1.03M <1.29F mmol/L)
4642 (38.7%) 4015 (25.5%) <0.001
LDL, mmol/L 2.930.86 2.770.84 <0.001
LDL ≥100 mg/dL
(≥2.59 mmol/L)
7602 (63.4%) 8881 (56.9%) <0.001
Systolic BP, mm Hg 14417 14317 <0.001
Diastolic BP, mm Hg 819 819 <0.001
BP ≥140/85 mm Hg 9397 (72.5%) 12 314 (72.6%) 0.498
Nonproliferative retinopathy 1645 (12.7%) 2310 (13.6%) 0.079
Proliferative retinopathy 500 (3.9%) 669 (3.9%) 0.565
Lipid-lowering treatment 794 (11.6%) 1841 (19.5%) <0.001
Treatment with statins 6395 (49.4%) 8184 (48.2%) 0.300
Treatment with fibrates 5979 (46.2%) 7477 (44.1%) 0.008
No. of antihypertensive drugs 246 (1.9%) 410 (2.4%) 0.008
Antihypertensive treatment 10 256 (79.2%) 12 850 (75.7%) <0.001
Treatment with ACE-Is/ARBs 8518 (65.8%) 10 994 (64.8%) 0.083
Aspirin 3543 (27.4%) 5753 (33.9%) <0.001
Antidiabetic therapy
Diet 838 (6.5%) 1339 (7.9%) <0.001
Oral antidiabetic drugs 8477 (65.4%) 11 660 (68.7%) <0.001
Oral antidiabetic
drugs and insulin
2285 (17.6%) 2274 (13.4%) <0.001
Continued
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Overall, the mean age was 659 years, 57% of patients
were men, and the mean duration of diabetes mellitus was
118 years. The glycometabolic status of participants was
fairly good, being the mean values of HbA1c and low-density
lipoprotein cholesterol of 7.31.3% and 11033 mg/dL,
respectively. The average BP was 14317/819 mm Hg,
with 73% of patients showing either SBP or DBP values above
140/85 mm Hg at the baseline visit. Seventy-seven percent
of patients were receiving antihypertensive treatment (with a
mean of 1.61.3 drugs per patient), and 65% were taking an
angiotensin-converting enzyme inhibitor or an angiotensin II
receptor antagonist. eGFR was 8613 mL/min per 1.73 m2,
and 19.6% of patients had increased albuminuria (Table 1).
The prevalence of aTRH was 16.6% (n=4989). The baseline
characteristics of patients with and without aTRH are also
detailed in Table 1. Those with aTRH were more likely to be
woman, older, with a longer duration of diabetes mellitus, and
to have higher body mass index as compared with those
without aTRH. On average, patients with aTRH had higher BP
and HbA1c values and lower total, low-density, and high-
density lipoprotein cholesterol levels than those without
aTRH. Moreover, the former group had lower eGFR, higher
serum uric acid levels, and were more likely to have Alb and
proliferative retinopathy. As expected, patients with aTRH
were more likely to be prescribed antihypertensive treatment
(especially with diuretics and renin-angiotensin-aldosterone
system–inhibiting agents) and lipid-lowering treatment.
Over the 4-year study follow-up, 19% (n=5707) developed
low eGFR, 12% (n=3551) an eGFR reduction ≥30% from
baseline, and 21% (n=6422) a combination of either 1 of the
above renal end points. Patients with aTRH showed a higher
cumulative incidence for renal end point and increased risk of
developing both renal outcome (adjusted OR, 1.31; CI, 1.19–
1.44; P<0.001; OR, 1.43, CI, 1.28–1.58; P<0.001; and OR,
1.30, CI, 1.19–1.42; P<0.001, respectively), as compared with
those without aTRH (Figure 2).
Baseline clinical features of patients grouped on the basis
of achieved renal outcome within the study period are
reported in Table 2. On average, patients who went on to
develop low eGFR, an eGFR reduction ≥30% from baseline, or
either 1 of the renal end points showed a worse clinical and
metabolic profile. They were older, with a longer duration of
diabetes mellitus, were more likely to be woman, and to show
albuminuria and proliferative retinopathy. Moreover, they had
lower GFR values and higher serum uric acid, HbA1c levels,
and BP values, with a greater prevalence of aTRH and similar
BPC despite a greater prevalence of antihypertensive and
insulin treatment.
BP changes during follow-up are shown in Figure 3.
Additional analyses explored the relationship between
different hypertension categories on the basis of aTRH and
time-updated BPC and renal outcomes. Individuals without
BPC were more likely to be woman, were older, and with a
longer duration of diabetes mellitus and higher body mass
index as compared with those with persistent BPC indepen-
dently of aTRH status (Table 3). On average, patients without
BPC had higher BP values and HbA1c and total, low-density,
and high-density lipoprotein cholesterol levels than those with
good BPC. Despite similar eGFR values, patients without
persistent BPC were more likely to show serum uric acid in
the top sex-specific quintile, Alb, and proliferative retinopathy.
As expected, patients without BPC were less likely to be
prescribed antihypertensive treatment (number of drugs
1.21.0 versus 1.60.9 for no aTRH; P<0.01; and 3.60.8
Table 5. Continued
Women Men
P Valuen=12 954 n=16 969
Insulin 1354 (10.5%) 1696 (10.0%) 0.123
Apparent resistant hypertension 2452 (18.9%) 2537 (15.0%) <0.001
BP control in at least 75% of
visits for GFR <60
1971 (15.2%) 2741 (16.2%) 0.010
BP control in at least 75% of visits
for GFR red >30%
1988 (15.3%) 2765 (16.3%) 0.010
BP control in at least 75% of visits for GFR <60 or red >30% 1982 (15.3%) 2741 (16.2%) 0.017
4-year outcome
GFR <60 2809 (21.7%) 2898 (17.1%) <0.001
GFR reduction >30% than baseline 1829 (14.1%) 1722 (10.1%) <0.001
GFR <60 or reduction >30% than baseline 3196 (24.7%) 3226 (19.0%) <0.001
Blood pressure control (BPC) refers to the proportion of visits with systolic and diastolic blood pressure <140/90 mm Hg. For each renal outcome, visits after the event occurrence were
excluded. Complete-case analysis including 29 923 patients for which all data were observed. ACE-Is indicates angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor
antagonists; BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-
density lipoprotein cholesterol; SUA, serum uric acid.
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Table 6. Baseline Characteristics of Study Patients Stratified by Age
<55 Years 56 to 65 Years >65 Years
P Valuen=4772 n=11 052 n=14 099
Male sex 3023 (63.3%) 6415 (58.0%) 7531 (53.4%) <0.001
Age, y 505 613 725 . . .
Known duration of
diabetes mellitus, y
76 98 139 <0.001
BMI, kg/m2 316 305 295 <0.001
Serum creatinine, lmol/L 7315 7415 7414 <0.001
eGFR, mL/min per 1.73 m2 9713 8812 8011 <0.001
Albuminuria 1031 (21.6%) 2083 (18.8%) 2760 (19.6%) <0.001
Microalbuminuria 889 (18.6%) 1819 (16.5%) 2413 (17.1%) 0.001
Macroalbuminuria 142 (3.0%) 264 (2.4%) 347 (2.5%) 0.139
Serum uric acid, lmol/L 31385 318106 314102 0.073
SUA in the top sex-specific
quintile
465 (19.7%) 1062 (19.4%) 1351 (19.1%) 0.809
HbA1c, % 7.41.5 7.31.3 7.21.2 <0.001
HbA1c, mmol/mol 5717 5614 5513 <0.001
HbA1c ≥7% (≥53 mmol/mol) 2504 (52.8%) 5859 (53.4%) 7624 (54.5%) 0.009
Total cholesterol, mmol/L 4.921.01 4.850.97 4.780.94 <0.001
Triglycerides, mmol/L 1.781.28 1.601.05 1.430.78 <0.001
Triglycerides ≥150 mg/dL
(≥1.69 mmol/L)
1751 (39.0%) 3548 (34.1%) 3481 (26.3%) <0.001
HDL, mmol/L 1.240.34 1.300.36 1.370.39 <0.001
HDL <40M <50F mg/dL
(<1.03M <1.29F mmol/L)
1666 (37.3%) 3402 (33.1%) 3589 (27.6%) <0.001
LDL, mmol/L 2.920.90 2.850.85 2.800.83 <0.001
LDL ≥100 mg/dL (≥2.59 mmol/L) 2773 (63.2%) 6155 (60.3%) 7555 (58.1%) <0.001
Systolic BP, mm Hg 13917 14217 14517 <0.001
Diastolic BP, mm Hg 849 829 809 <0.001
BP ≥140/85 mm Hg 3391 (71.1%) 7949 (71.9%) 10 371 (73.6%) <0.001
Nonproliferative retinopathy 537 (11.3%) 1424 (12.9%) 1994 (14.1%) <0.001
Proliferative retinopathy 154 (3.2%) 428 (3.9%) 587 (4.2%) 0.034
Lipid-lowering treatment 722 (25.9%) 1158 (18.8%) 755 (10.3%) <0.001
Treatment with statins 1973 (41.3%) 5538 (50.1%) 7068 (50.1%) <0.001
Treatment with fibrates 1714 (35.9%) 5078 (45.9%) 6664 (47.3%) <0.001
No. of antihypertensive drugs 172 (3.6%) 272 (2.5%) 212 (1.5%) <0.001
Antihypertensive treatment 3343 (70.1%) 8379 (75.8%) 11 384 (80.7%) <0.001
Treatment with ACE-Is/ARBs 2878 (60.3%) 7154 (64.7%) 9480 (67.2%) <0.001
Aspirin 921 (19.3%) 3299 (29.8%) 5076 (36.0%) <0.001
Antidiabetic therapy
Diet 403 (8.4%) 862 (7.8%) 912 (6.5%) <0.001
Oral antidiabetic drugs 3219 (67.5%) 7503 (67.9%) 9415 (66.8%) 0.077
Oral antidiabetic drugs and insulin 678 (14.2%) 1734 (15.7%) 2147 (15.2%) 0.018
Insulin 472 (9.9%) 953 (8.6%) 1625 (11.5%) <0.001
Continued
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versus 4.00.7 for aTRH; P<0.01) and lipid-lowering treat-
ment as compared with those with BPC.
When we performed a multivariate analysis, age, body
mass index, low eGFR, presence of Alb and of proliferative
retinopathy, worse lipid profile (suggestive of the insulin
resistance state), and the prescription of insulin and antihy-
pertensive treatment were significantly and independently
associated with a greater risk of incident eGFR below 60 mL/
min and renal function worsening, as indicated in Table 4. At
variance, we found no independent relationship between
known duration of diabetes mellitus, baseline HbA1c, and
several treatments for cardiovascular protection, such as
lipid-lowering treatment, renin-angiotensin-aldosterone sys-
tem inhibition, or aspirin, and anyone of the renal end points
taken into consideration in this generally well-treated study
cohort (Table 4).
The relationship between aTRH, BPC, and future develop-
ment of renal outcome was further investigated on the basis
of sex and age. Results (Tables 5 through 10) substantially
confirm main study findings and emphasize that renal risk is
particularly elevated in older patients, and in those with aTRH
reaching very low blood pressure values (ie, those with BPC).
Patients with aTRH showed an increased risk of developing
low eGFR and eGFR reduction ≥30% from baseline as
compared with those without aTRH. Furthermore, no associ-
ation was found between BPC and renal outcome in non-
aTRH, whereas in aTRH, BPC was associated with a 30%
(P=0.036) greater risk to develop either 1 of the renal end
points (Table 11).
We investigated changes in eGFR along the 4 years of
follow-up on the basis of aTRH and BPC. Associations
between changes in eGFR and the presence of aTRH and/or
BPC were examined using adjusted mean values of eGFR
slope. The yearly mean eGFR slope was significantly higher for
the aTRH patients as compared with those with no aTRH
independently of BPC. Thus, whereas BPC seems to confer
renal protection in patients without aTRH, those with aTRH
with and without BPC showed a very similar yearly mean eGFR
slope (Figure 4).
The presence of Alb was associated with worse renal
prognosis both in patients without aTRH (OR, 2.00; CI, 1.80–
2.23; P<0.001) and in those with aTRH (OR, 1.67; CI, 1.38–
2.02; P<0.001; Figure 5A). Furthermore, in the absence of
optimal BPC, the presence of Alb entailed greater incidence of
low eGFR (Alb+/BPC versus Alb/BPC; OR, 1.98; CI,
1.79–2.19; P<0.001), the unfavorable prognostic role of
increased Alb at baseline was unchanged when BPC was
obtained (Alb+/BPC+ versus Alb/BPC+; OR, 1.71; CI, 1.34–
2.18; P<0.001; Alb+/BPC+ versus ALB/BPC; OR, 0.90; CI,
0.72–1.14; P=0.379; Figure 5B).
When our data were evaluated on the basis of time-
updated mean SBP, it emerged that aTRH patients showed a
greater risk of developing low eGFR as compared with non-
aTRH patients over the entire range of BP (Figure 6).
Furthermore, whereas renal risk decreases along with BP
reduction and reaches a nadir between 140 and 120 mm Hg,
the achievement of lower SBP values entails a paradoxical
increase in the incidence of GFR reduction, thereby confirm-
ing the existence of a J-curve relationship between SBP and
renal function.
Discussion
Our study shows that, in a real-life clinical setting, in
hypertensive T2D patients with normal renal function, the
presence of aTRH entails a greater risk of developing CKD or a
significant worsening of eGFR over a 4-year follow-up period.
Furthermore, the achievement and maintenance of optimal
Table 6. Continued
<55 Years 56 to 65 Years >65 Years
P Valuen=4772 n=11 052 n=14 099
Apparent resistant hypertension 512 (10.7%) 1761 (15.9%) 2716 (19.3%) <0.001
BP control in at least 75% of visits for GFR <60 989 (20.7%) 1788 (16.2%) 1935 (13.7%) <0.001
BP control in at least 75% of visits for GFR red >30% 992 (20.8%) 1803 (16.3%) 1958 (13.9%) <0.001
BP control in at least 75% of visits for GFR <60 or red >30% 988 (20.7%) 1796 (16.3%) 1939 (13.8%) <0.001
4-year outcome
GFR <60 mL/min per 1.73 m2 274 (5.7%) 1519 (13.7%) 3914 (27.8%) <0.001
GFR reduction >30% than baseline 362 (7.6%) 1122 (10.2%) 2067 (14.7%) <0.001
GFR <60 or reduction >30% than baseline 458 (9.6%) 1836 (16.6%) 4128 (29.3%) <0.001
Blood pressure control (BPC) refers to the proportion of visits with systolic and diastolic blood pressure <140/90 mm Hg. For each renal outcome, visits after the event occurrence were
excluded. Complete-case analysis including 29 923 patients for which all data were observed. ACE-Is indicates angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor
antagonists; BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-
density lipoprotein cholesterol; SUA, serum uric acid.
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BPC does not seem to be associated with renal protection
over time.
Although several studies conducted on high-risk hyperten-
sive patients have previously shown that aTRH entails a
greater cardiovascular and mortality risk,6,10,13 to date only 2
studies have investigated long-term renal outcome, namely
the development of ESRD.12,22
In a secondary analysis of the ALLHAT (Antihypertensive
and Lipid-Lowering Treatment to Prevent Heart Attack Trial)
study, aTRH was associated with a 2-fold greater risk of ESRD,
especially in the presence of diabetes mellitus even after
adjustment for confounders such as baseline GFR values.22
Similarly, Sim et al12 in a retrospective analysis of the large
Kaiser Permanente cohort of general hypertensive patients
from southern California, reported a 30% greater risk of ESRD
over a 5-year follow-up period in the subgroup of patients with
RH.
Both these studies, however, included a relevant propor-
tion of patients with CKD at baseline. In fact, in the Kaiser
Permanente cohort, up to 30% of patients had CKD at baseline
and eGFR was, on average, 60 mL/min in the aTRH subgroup.
Furthermore, results from the ALLHAT study have been
questioned because of the specific intervention protocol and
definition of RH.
In a further, retrospective, cohort study conducted on
subjects with incident hypertension in a US Registry, those
Table 7. Multivariate Analysis by Sex for the Occurrence of 4-Year Renal Outcome eGFR <60 mL/min per 1.73 m2
Women Men
Odds Ratio (95% CI) P Value Odds Ratio (95% CI) P Value
Age (by 10 y) 1.51 (1.39–1.63) <0.001 1.48 (1.37–1.59) <0.001
Duration of diabetes mellitus (by 10 y) 0.97 (0.90–1.04) 0.375 1.02 (0.95–1.09) 0.616
BMI (by 5 kg/m2) 1.09 (1.04–1.15) 0.001 1.09 (1.02–1.16) 0.008
eGFR (by 10 mL/min per 1.73 m2) 0.42 (0.40–0.44) <0.001 0.38 (0.36–0.40) <0.001
Microalbuminuria 1.51 (1.29–1.78) <0.001 1.78 (1.57–2.03) <0.001
Macroalbuminuria 4.00 (2.76–5.80) <0.001 4.55 (3.54–5.86) <0.001
HbA1c ≥7% (≥53 mmol/mol) 1.08 (0.96–1.22) 0.218 1.05 (0.94–1.17) 0.419
Triglycerides ≥150 mg/dL (≥1.69 mmol/L) 1.09 (0.96–1.23) 0.192 1.26 (1.12–1.41) <0.001
HDL <40M <50F mg/dL (<1.03M <1.29F mmol/L) 1.06 (0.94–1.19) 0.350 1.13 (1.00–1.28) 0.043
LDL ≥100 mg/dL (≥2.59 mmol/L) 0.80 (0.71–0.89) <0.001 0.87 (0.78–0.97) 0.009
Nonproliferative retinopathy 1.13 (0.96–1.33) 0.131 1.07 (0.93–1.25) 0.350
Proliferative retinopathy 1.33 (1.02–1.73) 0.037 1.25 (0.98–1.61) 0.074
Lipid-lowering treatment 0.92 (0.82–1.03) 0.132 0.94 (0.84–1.06) 0.315
Antihypertensive treatment 1.49 (1.21–1.83) <0.001 1.36 (1.11–1.66) 0.003
Treatment with ACE-Is/ARBs 0.93 (0.79–1.09) 0.374 0.95 (0.81–1.12) 0.565
Aspirin 1.19 (1.05–1.35) 0.007 1.00 (0.88–1.12) 0.946
Antidiabetic therapy
Diet 0.76 (0.59–0.97) 0.029 0.69 (0.54–0.87) 0.002
Oral antidiabetic drugs 1.00 1.00
Oral antidiabetic drugs and insulin 1.26 (1.08–1.47) 0.003 1.25 (1.07–1.46) 0.006
Insulin 1.16 (0.97–1.40) 0.109 1.34 (1.13–1.59) 0.001
Group ATRH and BPC
No ATRH and BPC 1.00 1.00
No ATRH and No BPC 1.01 (0.85–1.19) 0.952 1.09 (0.93–1.28) 0.294
ATRH and BPC 1.56 (1.07–2.28) 0.022 2.01 (1.39–2.91) <0.001
ATRH and No BPC 1.18 (0.96–1.44) 0.110 1.47 (1.21–1.78) <0.001
Blood pressure control (BPC) refers to the proportion of visits with systolic and diastolic blood pressure <140/90 mm Hg. For each renal outcome, visits after the event occurrence were
excluded. Odds ratio for single renal outcome with 95% confidence interval (CI). Complete-case analysis including 10 614 women and 14 026 men for which all data were observed. ACE-Is
indicates angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor antagonists; ATRH, apparent treatment resistant hypertension; BMI, body mass index; BP, blood pressure;
eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol.
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who went on to develop RH, after multivariate adjustment,
were at higher risk for cardiovascular outcomes and for the
development of stage 3 CKD as compared with those with
non-RH over a 4-year follow-up.11
Our study is the first, to our knowledge, to investigate the
impact of aTRH on the early stages of kidney damage in a
high-renal-risk population of patients such as those with T2D
and hypertension. The choice of intermediate, but well-
established, end points such as the development of stage 3
CKD and a 30% reduction in eGFR, which have been shown to
predict and precede progression to ESRD,23,24 allowed us to
accurately investigate the onset of renal function impairment
over the 4 years of study follow-up.
The prevalence and clinical characteristics of patients with
aTRH we observed in the present study are comparable to
what has been previously reported in similar high-risk
groups.25 Over the follow-up period, in our generally well-
treated cohort, 19% of patients developed stage 3 CKD (ie, a
eGFR value below 60 mL/min) and 12% showed a significant
eGFR reduction (ie, ≥30%) from baseline. In patients with
aTRH, the presence of a worse cardiovascular risk profile,
namely older age, body mass index, a reduction in eGFR, a
worse lipid profile, or the presence of Alb or proliferative
retinopathy were independent predictors of worse renal
outcome. Furthermore, the presence of aTRH entailed a
faster decline in renal function over time, despite the
Table 8. Multivariate Analysis by Sex for the Occurrence of 4-Year Renal Outcome eGFR Reduction ≥30%
Women Men
Odds Ratio (95% CI) P Value Odds Ratio (95% CI) P Value
Age (by 10 y) 1.53 (1.41–1.66) <0.001 1.58 (1.45–1.72) <0.001
Duration of diabetes mellitus (by 10 y) 0.99 (0.91–1.07) 0.741 0.95 (0.88–1.02) 0.173
BMI (by 5 kg/m2) 1.07 (1.01–1.13) 0.017 1.10 (1.03–1.18) 0.006
eGFR (by 10 mL/min per 1.73 m2) 1.10 (1.04–1.16) <0.001 1.06 (1.00–1.12) 0.036
Microalbuminuria 1.53 (1.30–1.81) <0.001 1.92 (1.68–2.21) <0.001
Macroalbuminuria 3.99 (2.77–5.73) <0.001 4.21 (3.29–5.39) <0.001
HbA1c ≥7% (≥53 mmol/mol) 1.01 (0.88–1.15) 0.926 1.08 (0.95–1.23) 0.213
Triglycerides ≥150 mg/dL (≥1.69 mmol/L) 1.15 (1.01–1.32) 0.034 1.23 (1.08–1.39) 0.002
HDL <40M <50F mg/dL (<1.03M <1.29F mmol/L) 1.09 (0.96–1.23) 0.188 1.17 (1.02–1.34) 0.023
LDL ≥100 mg/dL (≥2.59 mmol/L) 0.77 (0.68–0.87) <0.001 0.82 (0.73–0.92) 0.001
Nonproliferative retinopathy 1.11 (0.93–1.32) 0.236 1.12 (0.95–1.32) 0.185
Proliferative retinopathy 1.24 (0.94–1.64) 0.130 1.19 (0.91–1.56) 0.212
Lipid-lowering treatment 0.88 (0.78–1.00) 0.054 0.97 (0.85–1.10) 0.589
Antihypertensive treatment 1.41 (1.13–1.76) 0.002 1.27 (1.01–1.59) 0.040
Treatment with ACE-Is/ARBs 0.91 (0.76–1.08) 0.258 0.94 (0.78–1.13) 0.511
Aspirin 1.07 (0.93–1.23) 0.324 0.97 (0.85–1.11) 0.682
Antidiabetic therapy
Diet 0.61 (0.44–0.84) 0.002 0.74 (0.56–0.97) 0.032
Oral antidiabetic drugs 1.00 1.00
Oral antidiabetic drugs and insulin 1.23 (1.04–1.44) 0.014 1.29 (1.09–1.53) 0.003
Insulin 1.31 (1.08–1.59) 0.006 1.11 (0.91–1.35) 0.310
Group ATRH and BPC
No ATRH and BPC 1.00 1.00
No ATRH and No BPC 0.86 (0.72–1.04) 0.113 1.15 (0.95–1.39) 0.149
ATRH and BPC 1.66 (1.14–2.43) 0.008 2.12 (1.44–3.13) <0.001
ATRH and No BPC 1.18 (0.96–1.46) 0.123 1.61 (1.29–2.00) <0.001
Blood pressure control (BPC) refers to the proportion of visits with systolic and diastolic blood pressure <140/90 mm Hg. For each renal outcome, visits after the event occurrence were
excluded. Odds ratio for single renal outcome with 95% confidence interval (CI). Complete-case analysis including 10 614 women and 14 026 men for which all data were observed. ACE-Is
indicates angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor antagonists; ATRH, apparent treatment resistant hypertension; BMI, body mass index; BP, blood pressure;
eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol.
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achievement of recommended BP values (Figure 4). As
expected, the presence of Alb was associated with a greater
risk of renal function loss in both aTRH and non-aTRH patients
(Figure 5A).
It has been proposed that the RH population has an
adverse physiology and is therefore at greater risk for
morbidity and mortality. Thus, pathogenetic mechanisms as
well as clinical characteristics underlying the development of
cardiovascular and renal events, including BP changes and
therapeutic strategies, deserve better understanding given
that this may lead to optimization of therapeutic strategies for
BP reduction and comorbidities.7
We sought to further categorize aTRH resistant hyperten-
sion on the basis of BPC. By looking at time-updated BPC, we
were able to assess the impact of BP reduction and of the
persistence of good BP values over time before each renal end
point was reached, if any (Table 11). Moreover, we found that
the cumulative incidence of stage 3 CKD in patients with low
Table 9. Multivariate Analysis by Groups of Age for the Occurrence of 4-Year Renal Outcome eGFR <60 mL/min per 1.73 m2
Age ≤55 Years Age 56 to 65 Years Age >65 Years
Odds Ratio (95% CI) P Value Odds Ratio (95% CI) P Value Odds Ratio (95% CI) P Value
Male sex 0.85 (0.62–1.16) 0.296 0.79 (0.68–0.90) 0.001 0.80 (0.73–0.89) <0.001
Age (by 10 y) 1.01 (0.72–1.41) 0.954 1.60 (1.25–2.05) <0.001 1.52 (1.37–1.69) <0.001
Duration of diabetes
mellitus (by 10 y)
0.94 (0.74–1.21) 0.635 0.92 (0.84–1.02) 0.113 1.03 (0.97–1.09) 0.400
BMI (by 5 kg/m2) 1.11 (0.97–1.26) 0.124 1.03 (0.96–1.10) 0.364 1.13 (1.07–1.19) <0.001
eGFR (by 10 mL/min per 1.73 m2) 0.53 (0.47–0.59) <0.001 0.43 (0.4–0.45) <0.001 0.36 (0.34–0.38) <0.001
Microalbuminuria 1.21 (0.83–1.75) 0.324 1.70 (1.42–2.03) <0.001 1.72 (1.51–1.96) <0.001
Macroalbuminuria 4.72 (2.68–8.30) <0.001 5.50 (3.94–7.69) <0.001 3.47 (2.60–4.65) <0.001
HbA1c ≥7% (≥53 mmol/mol) 1.05 (0.75–1.45) 0.789 1.03 (0.88–1.19) 0.736 1.08 (0.97–1.21) 0.137
Triglycerides ≥150 mg/dL
(≥1.69 mmol/L)
1.24 (0.91–1.70) 0.176 1.24 (1.07–1.43) 0.004 1.15 (1.03–1.28) 0.014
HDL <40M <50F mg/dL
(<1.03M <1.29F mmol/L)
1.07 (0.78–1.46) 0.692 1.02 (0.88–1.19) 0.776 1.12 (1.00–1.25) 0.048
LDL ≥100 mg/dL (≥2.59 mmol/L) 0.74 (0.54–1.00) 0.048 0.78 (0.68–0.89) <0.001 0.86 (0.78–0.95) 0.003
Nonproliferative retinopathy 1.05 (0.67–1.66) 0.827 1.10 (0.90–1.35) 0.337 1.13 (0.98–1.29) 0.084
Proliferative retinopathy 1.46 (0.75–2.85) 0.270 1.79 (1.32–2.44) <0.001 1.02 (0.81–1.30) 0.850
Lipid-lowering treatment 0.84 (0.62–1.16) 0.295 0.99 (0.85–1.14) 0.840 0.92 (0.83–1.02) 0.096
Antihypertensive treatment 2.01 (1.19–3.39) 0.009 1.50 (1.14–1.96) 0.003 1.32 (1.10–1.59) 0.003
Treatment with ACE-Is/ARBs 0.60 (0.39–0.93) 0.022 0.99 (0.79–1.23) 0.903 0.98 (0.85–1.12) 0.740
Aspirin 0.97 (0.66–1.42) 0.871 0.89 (0.76–1.05) 0.168 1.16 (1.04–1.29) 0.008
Antidiabetic therapy
Diet 0.79 (0.42–1.49) 0.466 0.65 (0.47–0.89) 0.007 0.73 (0.59–0.91) 0.005
Oral antidiabetic drugs 1.00 1.00 1.00
Oral antidiabetic drugs and insulin 1.59 (1.05–2.43) 0.030 1.41 (1.16–1.71) 0.001 1.15 (1.00–1.33) 0.051
Insulin 1.71 (1.06–2.74) 0.027 1.86 (1.48–2.34) <0.001 1.03 (0.88–1.21) 0.718
Group ATRH and BPC
No ATRH and BPC 1.00 1.00 1.00
No ATRH and No BPC 0.82 (0.56–1.20) 0.304 1.09 (0.89–1.33) 0.407 1.05 (0.90–1.23) 0.519
ATRH and BPC 1.83 (0.74–4.49) 0.190 1.51 (0.96–2.39) 0.077 1.96 (1.38–2.78) <0.001
ATRH and No BPC 1.60 (0.98–2.64) 0.063 1.55 (1.22–1.98) <0.001 1.20 (1.00–1.43) 0.050
Blood pressure control (BPC) refers to the proportion of visits with systolic and diastolic blood pressure <140/90 mm Hg. For each renal outcome, visits after the event occurrence were
excluded. Odds ratio for single renal outcome with 95% confidence interval (CI). Complete-case analysis including 3942 patients aged ≤55 years, 9133 aged 56 to 65 years, and 11 565
aged >65 years for which all data were observed. ACE-Is indicates angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor antagonists; ATRH, apparent treatment resistant
hypertension; BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-
density lipoprotein cholesterol.
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mean time-updated SBP (ie, <130 mm Hg) was greater than
that observed in patients who achieved less-tight BP reduction
independently of aTRH (Figure 6).
The subgroup of patients with tightly controlled hyperten-
sion not only had lower BP, but were also more likely to have a
statin prescription and to have lower values of low-density
lipoprotein cholesterol, a finding that makes low adherence to
prescribed medications an unlikely explanation for worse
renal outcomes.
Our results are in keeping with those reported by Egan
et al,15 who also found that tight control, as compared with
usual, is associated with worse cardiovascular outcomes both
in patients with and without aTRH. Along the same line, more
recently, in a pooled retrospective analysis of the Ontarget/
Transcend database,26 lowering BP to less than 130 mm Hg
SBP was found to be associated with increased rates for
cardiovascular events and mortality in patients at high
cardiovascular risk.
Table 10. Multivariate Analysis by Groups of Age for the Occurrence of 4-Year Renal Outcome eGFR Reduction ≥30%
Age ≤55 Years Age 56 to 65 Years Age >65 Years
Odds Ratio (95% CI) P Value Odds Ratio (95% CI) P Value Odds Ratio (95% CI) P Value
Male sex 0.75 (0.58–0.99) 0.039 0.69 (0.59–0.80) <0.001 0.75 (0.67–0.84) <0.001
Age (by 10 y) 1.42 (1.07–1.90) 0.016 1.37 (1.05–1.78) 0.019 1.59 (1.41–1.81) <0.001
Duration of diabetes
mellitus (by 10 y)
0.95 (0.76–1.19) 0.657 0.92 (0.83–1.02) 0.124 0.99 (0.92–1.05) 0.659
BMI (by 5 kg/m2) 1.02 (0.91–1.14) 0.736 1.04 (0.97–1.12) 0.230 1.12 (1.06–1.19) <0.001
eGFR (by 10 mL/min per 1.73 m2) 1.26 (1.13–1.40) <0.001 1.09 (1.02–1.16) 0.007 1.03 (0.98–1.09) 0.216
Microalbuminuria 1.51 (1.11–2.06) 0.009 1.72 (1.43–2.07) <0.001 1.80 (1.56–2.07) <0.001
Macroalbuminuria 4.24 (2.48–7.26) <0.001 4.80 (3.45–6.68) <0.001 3.48 (2.59–4.67) <0.001
HbA1c ≥7% (≥53 mmol/mol) 1.11 (0.83–1.47) 0.490 1.10 (0.94–1.29) 0.250 1.01 (0.90–1.14) 0.833
Triglycerides ≥150 mg/dL
(≥1.69 mmol/L)
1.28 (0.97–1.68) 0.075 1.26 (1.08–1.47) 0.003 1.13 (1.00–1.28) 0.058
HDL <40M <50F mg/dL
(<1.03M <1.29F mmol/L)
1.21 (0.92–1.58) 0.168 1.06 (0.91–1.25) 0.442 1.11 (0.98–1.26) 0.093
LDL ≥100 mg/dL (≥2.59 mmol/L) 1.03 (0.79–1.34) 0.818 0.72 (0.62–0.84) <0.001 0.79 (0.71–0.88) <0.001
Nonproliferative retinopathy 1.21 (0.82–1.78) 0.336 1.11 (0.90–1.37) 0.340 1.11 (0.95–1.30) 0.176
Proliferative retinopathy 1.91 (1.08–3.37) 0.026 1.47 (1.07–2.03) 0.019 0.97 (0.74–1.27) 0.829
Lipid-lowering treatment 0.98 (0.74–1.29) 0.881 1.00 (0.86–1.17) 0.955 0.88 (0.78–0.98) 0.026
Antihypertensive treatment 1.57 (0.99–2.48) 0.056 1.29 (0.97–1.71) 0.079 1.30 (1.05–1.60) 0.015
Treatment with ACE-Is/ARBs 0.68 (0.46–1.02) 0.062 0.99 (0.78–1.26) 0.948 0.96 (0.81–1.12) 0.584
Aspirin 0.95 (0.68–1.33) 0.764 0.98 (0.83–1.16) 0.812 1.05 (0.93–1.19) 0.448
Antidiabetic therapy
Diet 0.79 (0.44–1.41) 0.421 0.79 (0.56–1.12) 0.188 0.58 (0.43–0.78) <0.001
Oral antidiabetic drugs 1.00 1.00 1.00
Oral antidiabetic drugs and insulin 1.48 (1.04–2.12) 0.030 1.23 (1.00–1.51) 0.048 1.22 (1.05–1.43) 0.011
Insulin 1.16 (0.73–1.82) 0.532 1.89 (1.49–2.39) <0.001 0.94 (0.78–1.13) 0.497
Group ATRH and BPC
No ATRH and BPC 1.00 1.00 1.00
No ATRH and No BPC 0.86 (0.61–1.22) 0.408 1.03 (0.83–1.29) 0.794 1.00 (0.83–1.20) 0.995
ATRH and BPC 1.89 (0.79–4.55) 0.155 1.29 (0.78–2.16) 0.322 2.31 (1.63–3.29) <0.001
ATRH and No BPC 1.82 (1.17–2.85) 0.008 1.54 (1.19–2.00) 0.001 1.24 (1.01–1.52) 0.044
Blood pressure control (BPC) refers to the proportion of visits with systolic and diastolic blood pressure <140/90 mm Hg. For each renal outcome, visits after the event occurrence were
excluded. Odds ratio for single renal outcome with 95% confidence interval (CI). Complete-case analysis including 3942 patients aged ≤55 years, 9133 aged 56 to 65 years, and 11 565
aged >65 years for which all data were observed. ACE-Is indicates angiotensin-converting enzyme inhibitors; ARBs, angiotensin II receptor antagonists; ATRH, apparent treatment resistant
hypertension; BMI, body mass index; BP, blood pressure; eGFR, estimated glomerular filtration rate; HbA1c, glycated hemoglobin; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-
density lipoprotein cholesterol.
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The relationship between BPC and renal outcome in aTRH
has been, so far, investigated only in the analysis by Sim
et al, who observed a 25% greater risk for ESRD in
individuals with uncontrolled RH as compared with controlled
RH,12 a finding that seems to differ from those reported
here.
In the Kaiser Permanente study, however, only baseline BP
values were analyzed to assess the degree of BP control,
Table 11. Comparative Risk for Outcomes Among Different Hypertension Categories
eGFR <60 mL/min per 1.73 m2
No ATRH and BPC Reference 0.95 (0.85–1.07) P=0.393 0.56 (0.43–0.73) P<0.001 0.76 (0.66–0.87) P<0.001
No ATRH and No BPC 1.05 (0.94–1.18) P=0.393 Reference 0.59 (0.46–0.76) P<0.001 0.80 (0.72–0.88) P<0.001
ATRH and BPC 1.78 (1.37–2.32) P<0.001 1.69 (1.32–2.18) P<0.001 Reference 1.35 (1.04–1.75) P=0.024
ATRH and No BPC 1.32 (1.15–1.52) P<0.001 1.26 (1.13–1.39) P<0.001 0.74 (0.57–0.96) P=0.024 Reference
eGFR reduction ≥30%
No ATRH and BPC Reference 1.01 (0.88–1.14) P=0.940 0.54 (0.41–0.70) P<0.001 0.73 (0.63–0.85) P<0.001
No ATRH and No BPC 1.00 (0.87–1.13) P=0.940 Reference 0.53 (0.41–0.69) P<0.001 0.73 (0.65–0.81) P<0.001
ATRH and BPC 1.87 (1.43–2.45) P<0.001 1.88 (1.46–2.42) P<0.001 Reference 1.36 (1.05–1.77) P=0.020
ATRH and No BPC 1.37 (1.18–1.59) P<0.001 1.38 (1.23–1.54) P<0.001 0.73 (0.56–0.95) P=0.020 Reference
eGFR <60 or reduction ≥30%
No ATRH and BPC Reference 0.96 (0.87–1.07) P=0.486 0.59 (0.47–0.76) P<0.001 0.77 (0.68–0.87) P<0.001
No ATRH and No BPC 1.04 (0.93–1.16) P=0.486 Reference 0.62 (0.49–0.78) P<0.001 0.80 (0.73–0.88) P<0.001
ATRH and BPC 1.68 (1.32–2.15) P<0.001 1.62 (1.28–2.05) P<0.001 Reference 1.29 (1.02–1.65) P=0.036
ATRH and No BPC 1.30 (1.14–1.48) P<0.001 1.25 (1.14–1.38) P<0.001 0.77 (0.61–0.98) P=0.036 Reference
Multivariate odds ratios with 95% confidence interval for each renal outcome according to models listed in Table 4. ATRH indicates apparent treatment resistant hypertension; BPC, blood
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N of ptz 4198 20736 514 4475
Baseline eGFR
(ml/min/1.73m2)
86 14 86 13 83 13 83 13
Figure 4. Mean yearly eGFR slope on the basis of the presence of aTRH and BPC. ATRH indicates
apparent treatment resistant hypertension; eGFR, estimated glomerular filtration rate; BP, blood pressure
control (BPC) refers to the proportion of visits with systolic and diastolic blood pressure <140/90 mm Hg.
*P<0.01 vs No-aTRH with BPC; #P<0.01 vs No-aTRH with NoBPC.
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therefore assuming that once individuals are categorized at
baseline, they remain so thorough the observation period; in
contrast, our use of a dynamic indicator of BPC allowed us a
more-powerful representation of a real-world clinical scenario.
In fact, a significant proportion of patients (up to 20% in our
database over the study period) could have been misclassified
if analyzed only at baseline, given that both treatment and
degree of BPC could change over time.
In the presence of Alb, a well-known independent
predictor of unfavorable cardiovascular and renal prognosis
in patients with T2D and hypertension, a more-ambitious
target BP than the traditional 140/90 mm Hg has been
proposed by some guidelines to convey greater renal
protection.1,6 In our study, patients with Alb and BPC (ie,
<140/90) showed similar renal prognosis as compared with
those with less-tight BPC (Figure 5B). We performed further
analyses to assess whether, in the presence of micro- or
macro-Alb, achievement of very low BP values (ie, <130/
80 mm Hg) were associated with better renal outcome. We
found that patients with Alb with BP values below 130/80 in
at least 75% of study visits showed a 31% incidence of stage
3 CKD as compared with 26% in those with less-tight BP,
again suggesting the presence of a J-curve phenomenon,
which may limit renal protection.
Thus, the presence of aTRH entails a greater renal risk in
hypertensive patients with T2D as compared with non-aTRH
patients. The achievement and maintenance of recommended
BP values is associated with a worse renal prognosis even
more so when time-updated SBP is lowered below
120 mm Hg, a condition that is associated with increased
renal function loss even in non-aTRH patients.
Although the observational nature of our study does not
allow us to infer causality from reported associations, the
worse renal prognosis observed in patients with aTRH and
BPC supports the existence of a J-curve phenomenon linking
BP reduction and renal function.
Furthermore, we cannot rule out an unfavorable renal
effect of renin-angiotensin-aldosterone system I in frail, high-
risk patients as those with aTRH, where BP reduction was
obtained using a greater load of antihypertensive drugs
(Table 3), in particular renin-angiotensin-aldosterone system I.
In fact, it has recently been proposed that even mild GFR
reduction after initiation of treatment with angiotensin-
converting enzyme inhibitors or angiotensin II receptor
antagonists might entail a worse renal prognosis in the long
run,27 at least in a specific subgroup of patients, an issue that
is currently being investigated by specifically designed
ongoing studies.28
Our study has some limitations as well as several strengths
that should be mentioned. Among the first ones, we must
acknowledge that laboratory parameters, including serum
creatinine, were not measured in a single, centralized
laboratory and this may have led to some variability in GFR
estimation. We did not gather information on specific dosage
of antihypertensive medications prescribed to each patient to
confirm diagnosis of aTRH. However, BP control significantly
improved, on average, over the 4-year study period, suggest-
ing an attempt toward a therapeutic strategy of up-titration to
maximum tolerated dose. Furthermore, our data may not be
applicable to the population with T2D and hypertension at
large because the vast majority of participants were of white
origin, and ethnicity has previously been shown to bear some
impact on the risk of developing renal complications.29
Finally, we did not have information on extrarenal complica-
tions, such as myocardial infarction and stroke, which may
affect BP or renal function changes over time. On the other




















































Figure 5. A, Cumulative incidence of renal end point (eGFR
<60) on the basis of albuminuria status and aTRH. ALB indicates
albuminuria; ATRH, apparent treatment resistant hypertension; CI,
confidence interval; eGFR, estimated glomerular filtration rate.
*Adjusted odds ratios for Alb+/aTRH vs Alb/aTRH 2.00 (CI
1.80–2.23), P<0.001 and #for Alb+/aTRH+ vs Alb/aTRH+ 1.67
(CI 1.38–2.02), P<0.001. B, Cumulative incidence of renal end
point (eGFR <60) on the basis of albuminuria status and time-
updated BPC. ALB indicates albuminuria; BPC, blood pressure
control; eGFR, estimated glomerular filtration rate. *Adjusted
odds ratios for Alb+/BPC vs Alb/BPC 1.98 (CI 1.79–2.19),
P<0.001 and #for Alb+/BPC+ vs Alb/BPC+ 1.71 (CI 1.34–2.18),
P<0.001.
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of the study cohort, as well as the representative geographical
distribution of the recruiting centers and the relatively long
follow-up period, do contribute to make our results a reliable
representation of real-life clinical condition. Moreover, at
variance with several previous studies on the impact of RH on
cardiovascular and renal outcomes,10–15 we used a very
accurate definition of RH, which included the use of diuretics.
Another strength of our work is the use of time-updated BP
values as an indicator of achievement and maintenance of
BPC over time.
Further studies are clearly needed to investigate the
pathophysiological mechanism underlying the effect of BP
reduction per se as well as different pharmacological
strategies on renal outcome in high-risk hypertensive patients
such as those with diabetes mellitus.
In conclusion, our large, real-life cohort study shows that in
hypertensive patients with T2D, the presence of aTRH entails
a significantly greater risk of developing CKD and/or a
clinically relevant reduction in eGFR over a 4-year follow-up.
Interestingly, the achievement and maintenance of optimal BP
values are associated with worse renal outcome. The
relationship between achieved BP and renal function seems
to be J-shaped, at least at very low levels, with optimal SBP
values between 120 and 140 mm Hg.
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